성인 아토피피부염 환자에서 Lactobacillus rhamnosus (Lcr35)의 면역학적 변화
The Immunologic Effects of Lactobacillus rhamnosus (Lcr35) Supplements in Adult Patients with Atopic Dermatitis
1
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Background: Probiotics have recently been reported as a means of the prevention and treatment of atopic dermatitis (AD). However, detailed immune mechanisms involved in this effect remain speculative. The aim of this study was to investigate the effects of Lactobacillus rhamnosus (Lcr35) on symptoms of atopic dermatitis and cytokines production in peripheral blood monocytes (PBMCs). Method: Lcr35 was given to 5 adult patients with mild AD (2 males and 3 females; median SCORAD score, 15.2) for 4 weeks. We examined the SCORAD score and blood samples obtained in the initial, second, fourth and eighth weeks. We observed changes in production of IL-4, IFN-γ and IL-10 as well as responses to cell proliferation after stimulating PBMCs with Con-A. Result: There was no relevant significance in the SCORAD score before and after the treatment. PBMC proliferation was inhibited in the second and fourth weeks and was restored 1 month after the cessation of medication. IL-4 was decreased after the medication and persistently decreased after the cessation. IFN-γ was increased in the second week but decreased in the fourth week. IL-10 was increased in the second week (P=0.008) and showed variant patterns in the fourth week. Conclusion: The results of this study suggest that Lcr35 supplementation appears to modify cytokine production in PBMCs of AD patients. Further studies are needed to confirm this conclusion. (Korean J Asthma Allergy Clin Immunol 2008;28:128-133)
Abstract
Background: Probiotics have recently been reported as a means of the prevention and treatment of atopic dermatitis (AD). However, detailed immune mechanisms involved in this effect remain speculative. The aim of this study was to investigate the effects of Lactobacillus rhamnosus (Lcr35) on symptoms of atopic dermatitis and cytokines production in peripheral blood monocytes (PBMCs). Method: Lcr35 was given to 5 adult patients with mild AD (2 males and 3 females; median SCORAD score, 15.2) for 4 weeks. We examined the SCORAD score and blood samples obtained in the initial, second, fourth and eighth weeks. We observed changes in production of IL-4, IFN-γ and IL-10 as well as responses to cell proliferation after stimulating PBMCs with Con-A. Result: There was no relevant significance in the SCORAD score before and after the treatment. PBMC proliferation was inhibited in the second and fourth weeks and was restored 1 month after the cessation of medication. IL-4 was decreased after the medication and persistently decreased after the cessation. IFN-γ was increased in the second week but decreased in the fourth week. IL-10 was increased in the second week (P=0.008) and showed variant patterns in the fourth week. Conclusion: The results of this study suggest that Lcr35 supplementation appears to modify cytokine production in PBMCs of AD patients. Further studies are needed to confirm this conclusion. (Korean J Asthma Allergy Clin Immunol 2008;28:128-133)
참고문헌 (19)
- Oh JW, "Nationwide study for epidemiological change of atopic dermatitis in school aged children between 1995 and 2000 and kindergarten aged children in 2003 in Korea", Pediatr Allergy Respir Dis (Korea), 13, pp.227~237 (2003)
- Burke W, "Family history as a predictor of asthma risk", Am J Prev Med, 24, pp.160~169 (2003)
- Strachan DP, "Hay fever, hygiene, and household size", BMJ, 299, pp.1259~1260 (1989)
- Norin E, "Development of faecal short-chain fatty acid pattern during the first year of life in Estonia and Swedish infants", Microb Ecol Health Dis, 16, pp.8~12 (2004)
- Kalliomaki M, "Distinct patterns of neonatal gut microflora in infants developing or not developing atopy", J Allergy Clin Immunol, 107, pp.129~134 (2001)
- Kalliomaki M, "Probiotics in primary prevention of atopic disease: a randomized placebo-controlled trial", Lancet, 357, pp.1076~1079 (2001)
- Kalliomaki M, "Probiotics and prevention of atopic disease: 4-year follow-up of a randomized placebo-controlled trial", Lancet, 361, pp.1869~1871 (2003)
- Kalliomaki M, "Probiotics during the first 7 years of life; A cumulative risk reduction of eczema in a randomized, placebo-controlled trial", J Allergy Clin Immunol, 119, pp.1019~1021 (2007)
- Kirjavainen PV, "Probiotic bacteria in the management of atopic disease: underscoring the importance of viability", J Pediatr Gastroenterol Nutr, 36, pp.223~227 (2003)
- Rosenfelt V, "Effect of probiotic Lactobacillus strains in children with atopic dermatitis", J Allergy Clin Immunol, 111, pp.389~395 (2003)
- Weston S, "Effects of probiotics on atopic dermatitis: a randomized controlled trial", Arch Dis Child, 90, pp.892~897 (2005)
- Isolauri E, "Salminen S. Probiotics in the management of atopic eczema", Clin Exp Allergy, 30, pp.1604~1610 (2000)
- Matsumoto M, "LKM512 yogurt consumption improves the intestinal environment and induces the T-helper type 1 cytokine in adult patients with intractable atopic dermatitis", Clin Exp Allergy, 37, pp.358~370
- Smits HH, "Selective probiotic bacteria induce IL-10 producing regulatory T cells in vitro by modulating dendritic cell function through dendritic cell-specific intercellular adhesion molecule 3-grabbing nonintegrin", J Allergy Clin Immunol, 115, pp.1260~1267 (2005)
- Pessi T, "Interleukin-10 generation in atopic children following oral Lactobacillus rhamnosus GG", Clin Exp Allergy, 30, pp.1804~1808 (2000)
- Pochard P, "Lactic acid bacteria inhibit TH2 cytokine production by mononuclear cells from allergic patients", J Allergy Clin Immunol, 110, pp.617~623 (2002)
- Pohjavuori E, "Lactobacillus GG effect in increasing IFN-γ production in infants with cow’s milk allergy", J Allergy Clin Immunol, 114, pp.131~136 (2004)
- Dunstan JA, "Atopic dermatitis in young children is associated with impaired interleukin-10 and interferon-γ responses to allergens, vaccines and colonizing skin and gut bacteria", Clin Exp Allergy, 35, pp.1309~1317 (2005)
- Kong DY, "The effects on treatment of atopic dermatitis with oral Lactobacillus casei supplements in Korean children", Pediatr Respir Dis (Korea), 17, pp.27~37 (2007)